Does Rallies show Form 4 insider transactions for AVTX?

Yes. Rallies tracks AVTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AVTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AVTX. It does not provide personalized investment advice.

AVTX (Avalo Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Avalo Therapeutics, Inc. Common Stock (AVTX) is a publicly traded Healthcare sector company. As of May 21, 2026, AVTX trades at $16.31 with a market cap of $849.46M and a P/E ratio of -2.79. AVTX moved +0.15% today. Year to date, AVTX is +1.62%; over the trailing twelve months it is +297.32%. Its 52-week range spans $3.39 to $24.27. Analyst consensus is strong buy with an average price target of $46.78. Rallies surfaces AVTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AVTX stock inside the company?

Recent AVTX insider activity includes Sullivan Christopher Ryan sold 18.61K, VARKI PAUL sold 37.38K, VARKI PAUL sold 5.20K, VARKI PAUL sold 22.84K, and VARKI PAUL sold 9.25K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AVTX Key Metrics

Key financial metrics for AVTX
Metric	Value
Price	$16.31
Market Cap	$849.46M
P/E Ratio	-2.79
EPS	$-5.84
Dividend Yield	0.00%
52-Week High	$24.27
52-Week Low	$3.39
Volume	26
Avg Volume	0
Revenue (TTM)	$59.00K
Net Income	$-78.26M
Gross Margin	0.00%

Recent AVTX Insider Trades

Sullivan Christopher Ryan sold 18.61K (~$448.82K) on May 7, 2026.
VARKI PAUL sold 37.38K (~$706.84K) on May 6, 2026.
VARKI PAUL sold 5.20K (~$102.78K) on May 6, 2026.
VARKI PAUL sold 22.84K (~$484.54K) on May 6, 2026.
VARKI PAUL sold 9.25K (~$210.03K) on May 6, 2026.

Latest AVTX News

Avalo Reports 42.9% HiSCR75 Response, Raises $431.3M in Offering — May 13, 2026
Avalo Therapeutics Prices $375M Offering of 19.7M Shares and 1.4M Warrants — May 6, 2026
Avalo Therapeutics Posts 42% HiSCR75 Responses, Targets Phase 3 for Abdakibart — May 5, 2026
Avalo Pays $2.25M Upfront to Cap $15M Phase 3 Milestone Liability — Apr 28, 2026
Avalo Therapeutics Eyes Q2 2026 LOTUS Data, Secures $98M Runway — Mar 23, 2026

AVTX Analyst Consensus

9 analysts cover AVTX: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $46.78.

Common questions about AVTX

Who is trading AVTX stock inside the company?: Recent AVTX insider activity includes Sullivan Christopher Ryan sold 18.61K, VARKI PAUL sold 37.38K, VARKI PAUL sold 5.20K, VARKI PAUL sold 22.84K, and VARKI PAUL sold 9.25K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AVTX?: Yes. Rallies tracks AVTX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AVTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AVTX. It does not provide personalized investment advice.